Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Instructions to Expand Your Advantages from an Open Record Reward - 2This Unique National Park In Canada Is Famous For Its Otherworldly Limestone Monoliths
- 3A definitive Bike Standoff: Decision in favor of Your Number one Ride
- 4Whale stranded off Germany for days found stuck again
- 5How did birds survive while dinosaurs went extinct?
- This Luxurious Thermal Spa In Italy Is Perfect For A Relaxing Escape While Visiting Milan
- Gartex Texprocess India to showcase innovations across textile ecosystem
- The Best Web-based Courses for Expertise Improvement
- Audits of the Top Science fiction Movies This Year
- Iran war triggering Easter staycation boom
- Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- Louisiana seeks California doctor’s extradition, testing the limits of shield laws
- What's Your Number one Superhuman Film Made?
- German police 'cleared path for fascists with batons,' protesters say
